Page last updated: 2024-11-06

leupeptin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Leupeptin is a naturally occurring peptide derived from the bacterium Streptomyces violaceoruber. It is a potent inhibitor of various proteases, particularly cysteine proteases like cathepsin B and cathepsin L. Leupeptin inhibits these proteases by binding to their active site, preventing them from breaking down proteins. Leupeptin has been extensively studied for its potential therapeutic applications, particularly in the treatment of diseases involving inflammation, cancer, and neurodegenerative disorders. It has been shown to inhibit the breakdown of proteins involved in inflammation, reduce tumor growth, and protect against neuronal damage. Researchers are also exploring its potential in treating other conditions like Alzheimer's disease and Parkinson's disease. However, leupeptin has limited clinical use due to its poor bioavailability and potential toxicity. Currently, research is ongoing to develop more potent and less toxic leupeptin analogs for potential therapeutic use.'

Cross-References

ID SourceID
PubMed CID72429
CHEMBL ID191881
CHEBI ID6426
SCHEMBL ID583830
MeSH IDM0102237

Synonyms (55)

Synonym
n-acetyl-l-leucyl-n-[(1s)-4-{[amino(imino)methyl]amino}-1-formylbutyl]-l-leucinamide
IDI1_002183
BIO2_000428
BIO2_000908
n-acetyl-l-leucyl-l-leucyl-l-arginine, aldehyde deriv.
ac-leu-leu-arg-h
ac-leu-leu-arg-h; n-acetyl-l-leucyl-l-leucyl-l-arginine, aldehyde deriv
l-leucinamide, n-acetyl-l-leucyl-n-[(1s)-4-[(aminoiminomethyl)amino]-1-formylbutyl]-
BSPBIO_001195
leupeptin ,
NCGC00163460-01
(s)-2-(2-acetamido-4-methylvaleramido)-n-(1-formyl-4-guanidinobutyl)-4-methyl-valeramide
valeramide, 2-(2-acetamido-4-methylvaleramido)-n-(1-formyl-4-guanidinobutyl)-4-methyl- (s)-
KBIO2_005671
KBIO2_003103
KBIOSS_000535
KBIOGR_000535
KBIO3_000970
KBIO2_000535
KBIO3_000969
(s)-2-acetamido-n-((s)-1-((s)-5-guanidino-1-oxopentan-2-ylamino)-4-methyl-1-oxopentan-2-yl)-4-methylpentanamide
NCGC00163460-02
HMS1990K17
(2s)-2-acetamido-n-[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-4-methylpentanamide
HMS1362K17
HMS1792K17
CHEMBL191881
55123-66-5
unii-j97339nr3v
j97339nr3v ,
acetyl-l-leucyl-l-leucyl-l-argininal
l-leucinamide, n-acetyl-l-leucyl-n-(4-((aminoiminomethyl)amino)-1-formylbutyl)-, (s)-
l-leucinamide, n-acetyl-l-leucyl-n-((1s)-4-((aminoiminomethyl)amino)-1-formylbutyl)-
leupeptins [mi]
acetyl-leucyl-leucyl-argininal
SCHEMBL583830
L-4440
leupeptin (hemisulfate)
ac-llr-h
CHEBI:6426 ,
ac-l-leu-l-leu-l-arg-h
n-acetyl-leucylleucylargininal
n-acetyl-l-leucyl-n-[(2s)-5-carbamimidamido-1-oxopentan-2-yl]-l-leucinamide
GDBQQVLCIARPGH-ULQDDVLXSA-N
l-leucinamide, n-acetyl-l-leucyl-n-[4-[(aminoiminomethyl)amino]-1-formylbutyl]-
AKOS024456431
HMS3403K17
ac-leu-leu-argininal
DTXSID1020776
bdbm50213272
Q11350119
NCGC00163460-03
CS-0007311
HY-18234
AC-35848

Research Excerpts

Overview

Leupeptin is a small peptide microbially derived inhibitor of certain proteolytic enzymes. It is an established, reversible inhibitor of cathepsin B, a lysosomal cysteine proteinase.

ExcerptReferenceRelevance
"Leupeptin is a tight-binding inhibitor of cysteine proteinases, and its complex with cathepsin L is stable in alkaline solutions."( Gelatin Zymography Using Leupeptin for the Detection of Various Cathepsin L Forms.
Hashimoto, Y, 2017
)
1.48
"Leupeptin, known to be an inhibitor of cathepsin B both in vitro and after a single injection in vivo, paradoxically induced an increase of cathepsin B activity in mouse skeletal muscles after repeated administration."( Effects of the protease inhibitor leupeptin on proteolytic activities and regeneration of mouse skeletal muscles after exercise injuries.
Salminen, A, 1984
)
1.27
"Leupeptin is a potent inhibitor of cathepsin B in vitro and is presumed to act in a similar manner in vivo. "( Paradoxical effect of leupeptin in vivo on cathepsin B activity.
Greenbaum, LM; Sutherland, JH, 1983
)
2.02
"Leupeptin is an established, reversible inhibitor of cathepsin B, a lysosomal cysteine proteinase. "( Increased activities of cathepsin B and other lysosomal hydrolases in fibroblasts and bone tissue cultured in the presence of cysteine proteinases inhibitors.
Delaissé, JM; Kishore, BK; Montenez, JP; Tulkens, PM, 1994
)
1.73
"Leupeptin is a small peptide microbially derived inhibitor of certain proteolytic enzymes. "( Separation, purification and N-terminal sequence analysis of a novel leupeptin-sensitive serine endopeptidase present in chemically induced rat mammary tumour.
Eto, I; Grubbs, CJ, 1992
)
1.96

Effects

Leupeptin has no effect on the presentation of OVA peptides by LS.102.9 to the T-T hybrids. Leupeptin does not inhibit cellular degradation of EGF, despite its demonstrated ability to do so.

ExcerptReferenceRelevance
"Leupeptin has no effect on the presentation of OVA peptides by LS.102.9 to the T-T hybrids."( The generation of immunogenic peptides can be selectively increased or decreased by proteolytic enzyme inhibitors.
Benacerraf, B; Rock, KL; Vidard, L, 1991
)
1
"Leupeptin has no effect on the toxicity of either chimeric conjugate on any of the four cell lines, effect on the toxicity of either chimeric conjugate on any of the four cell lines, despite its demonstrated ability to inhibit cellular degradation of EGF."( An epidermal growth factor-ricin A chain (EGF-RTA)-resistant mutant and an epidermal growth factor-Pseudomonas endotoxin (EGF-PE)-resistant mutant have distinct phenotypes.
Banker, DE; Gottesman, MM; Herschman, HR; Pastan, I, 1989
)
1
"Leupeptin has no effect on acid lipases; therefore lipids do not accumulate in AVs of hepatocytes that are exposed to le"( Comparison of different autophagic vacuoles with regard to ultrastructure, enzymatic composition, and degradation capacity--formation of crinosomes.
Ahlberg, J; Glaumann, H, 1987
)
0.99

Actions

ExcerptReferenceRelevance
"Leupeptin does not inhibit serotonin release and aggregation induced by other platelet stimuli such as collagen, platelet-activating factor, ionophore A23187, and arachidonic acid."( Leupeptin selectively inhibits human platelet responses induced by thrombin and trypsin; a role for proteolytic activation of phospholipase C.
Lapetina, EG; Ruggiero, M, 1985
)
2.43

Treatment

Lupeptin did not increase enzymic activity levels in normal, GM1-gangliosidosis or I-cell disease fibroblasts. Leupeptin treatment did not change the hepatic activities and subcellular distribution of marker enzymes for mitochondria, microsomes and plasma membranes.

ExcerptReferenceRelevance
"Leupeptin treatment strongly reduces the amount of heat-labile class II molecules but does not impair peptide loading when DR3-specific peptides were added to viable cells or to cell lysates."( Acquisition of peptides by MHC class II polypeptides in the absence of the invariant chain.
Hitzel, C; Koch, N; van Endert, P, 1995
)
1.01
"Leupeptin treatment did not increase enzymic activity levels in normal, GM1-gangliosidosis or I-cell disease fibroblasts, despite the fact that the production of the 50 kDa and 18 kDa degradation products was blocked in the pre"( Early proteolytic cleavage with loss of a C-terminal fragment underlies altered processing of the beta-galactosidase precursor in galactosialidosis.
Callahan, JW; Hilson, W; Hinek, A; Okamura-Oho, Y; Zhang, S, 1996
)
1.02
"The leupeptin-treated rats showed good retention for 7 days following training; however, pronounced impaired retention was observed on day 10 and thereafter."( Memory disturbance and hippocampal degeneration induced by continuous intraventricular infusion of a protease inhibitor, leupeptin.
Arai, T; Ikarashi, Y; Kuribara, H; Maruyama, Y; Okamoto, K, 1997
)
0.99
"Leupeptin treatment to vitamin E-deficient rats only slightly reduced food intake and growth rates, and did not significantly modify the relative organ weights or the serum levels of cholesterol, GOT and GPT."( Effects of lovastatin and leupeptin on ceroidogenesis of vitamin E-deficient and -supplemented young rats.
Berra, A; Monserrat, AJ; Porta, EA; Rubio, MC, 1989
)
1.3
"Leupeptin treatment did not change the hepatic activities and subcellular distribution of marker enzymes for mitochondria, microsomes and plasma membranes."( Leupeptin as a tool for the detection of the sites of catabolism of rat high-density lipoprotein apolipoproteins A-I and E.
Dallinga-Thie, GM; van 't Hooft, FM; van Tol, A, 1985
)
2.43
"Leupeptin treatment led to a slight increase in the amount of 54-kd and 32-kd polypeptides in both late-infantile galactosialidosis cell lines."( The presence of a reduced amount of 32-kd "protective" protein is a distinct biochemical finding in late infantile galactosialidosis.
d'Azzo, A; Giudice, C; Hoogeveen, AT; Lijoi, S; Parenti, G; Strisciuglio, P, 1988
)
1
"In leupeptin-treated cells, HRP reaction product and variable amounts of membrane-bound Fer particles were found in apical vacuoles after 5 min; after 15 min, both labels were also observed in some small lysosomes, and after 60 min, they were found in all apical vacuoles as well as some small and middle-sized lysosomes."( Effects of leupeptin on endocytosis and membrane recycling in rat visceral yolk-sac endoderm.
Kugler, P; Miki, A, 1986
)
1.17
"Leupeptin-treated hepatocytes displayed more frequent and larger AVs than those of control livers."( Degradation of short- and long-lived proteins in perfused liver and in isolated autophagic vacuoles--lysosomes.
Ahlberg, J; Berkenstam, A; Glaumann, H; Henell, F, 1987
)
0.99
"Treatment with leupeptin restored flurazepam lowered receptor surface levels, strongly suggesting that flurazepam increases lysosomal degradation of GABA(A)Rs."( Benzodiazepine treatment induces subtype-specific changes in GABA(A) receptor trafficking and decreases synaptic inhibition.
Haydon, J; Jacob, TC; Michels, G; Moss, SJ; Silayeva, L; Succol, F, 2012
)
0.72
"Treatment with leupeptin recovered cardiac contractile function and attenuated calpain activity in IR hearts."( The sarcoplasmic reticulum proteins are targets for calpain action in the ischemic-reperfused heart.
Chohan, PK; Dhalla, NS; Netticadan, T; Singh, RB, 2004
)
0.66
"Pretreatment with leupeptin (3 mg/kg) abolished ASC-induced impairment of NANC inhibitory activities."( Dysfunction of nonadrenergic noncholinergic inhibitory system after antigen inhalation in actively sensitized cat airways.
Ichinose, M; Inoue, H; Katsumata, U; Kimura, K; Miura, M; Takahashi, T; Takishima, T, 1992
)
0.61

Toxicity

Abeta40 plus leupeptin induced intracellular accumulation of the more toxic Abeta, Abeta42, in a small group of septal neurons. Leupeptin was less toxic but resulted in definite morphological alteration of the cells.

ExcerptReferenceRelevance
" Intriguingly, Abeta40 plus leupeptin induced intracellular accumulation of the more toxic Abeta, Abeta42, in a small group of septal neurons."( Protease inhibitor coinfusion with amyloid beta-protein results in enhanced deposition and toxicity in rat brain.
Cole, GM; Frautschy, SA; Harris-White, ME; Horn, DL; Mendoza, JJ; Saido, TC; Sigel, JJ; Yang, F, 1998
)
0.59
" Leupeptin, an inhibitor acting on a broad spectrum of cellular serine proteases, was less toxic but resulted in definite morphological alteration of the cells."( Differential toxicity of protease inhibitors in cultures of cerebellar granule neurons.
Contestabile, A; Monti, B; Sparapani, M, 1998
)
1.21

Bioavailability

ExcerptReferenceRelevance
" It is produced as a latent complex and the main limiting step in TGFbeta bioavailability is its activation."( Tryptase activates TGFbeta in human airway smooth muscle cells via direct proteolysis.
Jenkins, G; Knox, A; Pang, L; Porte, J; Tatler, AL, 2008
)
0.35

Dosage Studied

Lupeptin had no effect on the repair process of skeletal muscle after exercise injuries. Several proteolytic processes occur during the regeneration. Results of a controlled, dose-response study indicated that leupeptin was absorbed into plasma by the oral route of administration.

ExcerptRelevanceReference
" Dose-response studies showed, however, that the State 2 pathway was more sensitive to leupeptin or monensin than the State 1 pathway."( Differential effects of leupeptin, monensin and colchicine on ligand degradation mediated by the two asialoglycoprotein receptor pathways in isolated rat hepatocytes.
Clarke, BL; Weigel, PH, 1989
)
0.81
" This method is simple and sensitive enough to permit the quantification of leupeptin in biological samples from mice dosed with leupeptin."( High-performance liquid chromatographic method for monitoring leupeptin in mouse serum and muscle by pre-column fluorescence derivatization with benzoin.
Ishida, J; Kai, M; Miura, T; Ohkura, Y, 1985
)
0.74
" At the low dosage used, leupeptin had no effect on the repair process of skeletal muscle after exercise injuries, although several proteolytic processes occur during the regeneration."( Effects of the protease inhibitor leupeptin on proteolytic activities and regeneration of mouse skeletal muscles after exercise injuries.
Salminen, A, 1984
)
0.85
" Results of a controlled, dose-response study indicated that leupeptin was absorbed into plasma by the oral route of administration."( Neuromuscular recovery after peripheral nerve repair: effects of an orally-administered peptide in a primate model.
Badalamente, MA; Hurst, LC; Stracher, A, 1995
)
0.53
"" While investigators continue to examine the best dosing paradigms for gentamicin in the treatment of Ménière's disease and for steroids in the treatment of hearing loss, they have also begun to focus on the use of other agents."( Sustained-release delivery of leupeptin in the chinchilla: hearing results.
Balough, BJ; Finley, JC; Gottshall, KR; Hoffer, ME; Killian, P; Shulman, A; Wester, D, 2003
)
0.61
" While repeated dosing with the milder 75 mg/kg dose did not cause mitochondrial protein adduct formation, JNK activation, or liver injury, autophagy inhibition resulted in hepatocyte death even at this lower dose."( Impaired protein adduct removal following repeat administration of subtoxic doses of acetaminophen enhances liver injury in fed mice.
Akakpo, JY; Ding, WX; Jaeschke, H; Nguyen, NT; Ramachandran, A; Weemhoff, JL, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
serine protease inhibitorAny protease inhibitor that restricts the action of a serine protease.
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
cathepsin B inhibitorA cysteine protease inhibitor which inhibits cathepsin B (EC 3.4.22.1).
calpain inhibitorAn EC 3.4.22.* (cysteine endopeptidase) inhibitor that interferes with the action of any calpain.
EC 3.4.21.4 (trypsin) inhibitorAn EC 3.4.21.* (serine endopeptidase) inhibitor that interferes with the action of trypsin (EC 3.4.21.4).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
tripeptideAny oligopeptide that consists of three amino-acid residues connected by peptide linkages.
aldehydeA compound RC(=O)H, in which a carbonyl group is bonded to one hydrogen atom and to one R group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
COVID-19, thrombosis and anticoagulation75
Wnt myofibroblastic activation of hepatic stellate cells02

Protein Targets (24)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cathepsin B Capra hircus (goat)Ki0.00630.00000.63811.9000AID1125413; AID1179620
Prothrombin Bos taurus (cattle)IC50 (µMol)12.00000.00890.88576.0000AID213261
PlasminogenHomo sapiens (human)IC50 (µMol)1.20000.02503.628010.0000AID378554
Cationic trypsinBos taurus (cattle)IC50 (µMol)8.10000.00003.479210.0000AID215017
TrypsinSus scrofa (pig)IC50 (µMol)0.35000.50000.50000.5000AID1177402; AID1177403
PapainCarica papaya (papaya)IC50 (µMol)0.00220.00201.504510.0000AID1698171
Plasma kallikreinHomo sapiens (human)IC50 (µMol)40.00000.00312.024110.0000AID95170
Serine protease hepsinHomo sapiens (human)Ki0.06100.00050.19170.8350AID1171341
Plasminogen Bos taurus (cattle)IC50 (µMol)3.70003.70003.70003.7000AID157792
Trypsin-1Homo sapiens (human)IC50 (µMol)0.60000.00351.532110.0000AID1886555
Trypsin-2Homo sapiens (human)IC50 (µMol)0.60000.00351.58464.4000AID1886555
Cathepsin BBos taurus (cattle)IC50 (µMol)0.31000.02000.09130.3100AID50109
Procathepsin LHomo sapiens (human)IC50 (µMol)0.00450.00021.66619.5100AID51214; AID51350
Cathepsin BHomo sapiens (human)IC50 (µMol)0.02820.00021.845310.0000AID351454; AID50272
Cathepsin BHomo sapiens (human)Ki0.00630.00001.21808.6000AID1125414; AID1179618; AID750031
Pro-cathepsin HHomo sapiens (human)Ki9.20009.20009.20009.2000AID1125415; AID1179619
Trypsin-3Homo sapiens (human)IC50 (µMol)0.60000.00351.58464.4000AID1886555
Calpain-1 catalytic subunitSus scrofa (pig)IC50 (µMol)0.08000.00751.52857.5000AID257051
Cathepsin KHomo sapiens (human)Ki0.02400.00000.15372.1000AID1432750
Hepatocyte growth factor activatorHomo sapiens (human)Ki0.18800.02500.07930.1880AID1171339
Transmembrane protease serine 6Homo sapiens (human)Ki3.25000.00421.18944.1000AID499180; AID499181
Cysteine proteaseLeishmania donovaniIC50 (µMol)0.01000.01000.08500.1600AID261351
Cysteine proteinase falcipain 2a Plasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)0.06360.00580.44035.0000AID240752; AID581959; AID581960
Cysteine protease falcipain-3Plasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)0.09250.08700.22220.4815AID581965; AID581966
Suppressor of tumorigenicity 14 proteinHomo sapiens (human)Ki1.29800.00000.87113.3500AID1171340; AID499182
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (108)

Processvia Protein(s)Taxonomy
proteolysisProthrombin Bos taurus (cattle)
acute-phase responseProthrombin Bos taurus (cattle)
positive regulation of blood coagulationProthrombin Bos taurus (cattle)
protein polymerizationProthrombin Bos taurus (cattle)
proteolysisPlasminogenHomo sapiens (human)
blood coagulationPlasminogenHomo sapiens (human)
negative regulation of cell population proliferationPlasminogenHomo sapiens (human)
negative regulation of cell-substrate adhesionPlasminogenHomo sapiens (human)
extracellular matrix disassemblyPlasminogenHomo sapiens (human)
tissue regenerationPlasminogenHomo sapiens (human)
fibrinolysisPlasminogenHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationPlasminogenHomo sapiens (human)
myoblast differentiationPlasminogenHomo sapiens (human)
muscle cell cellular homeostasisPlasminogenHomo sapiens (human)
tissue remodelingPlasminogenHomo sapiens (human)
biological process involved in interaction with symbiontPlasminogenHomo sapiens (human)
negative regulation of fibrinolysisPlasminogenHomo sapiens (human)
positive regulation of fibrinolysisPlasminogenHomo sapiens (human)
trophoblast giant cell differentiationPlasminogenHomo sapiens (human)
labyrinthine layer blood vessel developmentPlasminogenHomo sapiens (human)
mononuclear cell migrationPlasminogenHomo sapiens (human)
trans-synaptic signaling by BDNF, modulating synaptic transmissionPlasminogenHomo sapiens (human)
negative regulation of cell-cell adhesion mediated by cadherinPlasminogenHomo sapiens (human)
proteolysisCationic trypsinBos taurus (cattle)
digestionCationic trypsinBos taurus (cattle)
Factor XII activationPlasma kallikreinHomo sapiens (human)
proteolysisPlasma kallikreinHomo sapiens (human)
blood coagulationPlasma kallikreinHomo sapiens (human)
zymogen activationPlasma kallikreinHomo sapiens (human)
plasminogen activationPlasma kallikreinHomo sapiens (human)
fibrinolysisPlasma kallikreinHomo sapiens (human)
positive regulation of fibrinolysisPlasma kallikreinHomo sapiens (human)
proteolysisSerine protease hepsinHomo sapiens (human)
regulation of cell shapeSerine protease hepsinHomo sapiens (human)
positive regulation of gene expressionSerine protease hepsinHomo sapiens (human)
negative regulation of epithelial to mesenchymal transitionSerine protease hepsinHomo sapiens (human)
positive regulation of plasminogen activationSerine protease hepsinHomo sapiens (human)
positive regulation of cell growthSerine protease hepsinHomo sapiens (human)
basement membrane disassemblySerine protease hepsinHomo sapiens (human)
negative regulation of apoptotic processSerine protease hepsinHomo sapiens (human)
positive regulation by host of viral transcriptionSerine protease hepsinHomo sapiens (human)
negative regulation of epithelial cell proliferationSerine protease hepsinHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of soundSerine protease hepsinHomo sapiens (human)
potassium ion transmembrane transportSerine protease hepsinHomo sapiens (human)
cochlea morphogenesisSerine protease hepsinHomo sapiens (human)
response to thyroid hormoneSerine protease hepsinHomo sapiens (human)
pilomotor reflexSerine protease hepsinHomo sapiens (human)
positive regulation of hepatocyte proliferationSerine protease hepsinHomo sapiens (human)
positive regulation of thyroid hormone generationSerine protease hepsinHomo sapiens (human)
blood coagulationPlasminogen Bos taurus (cattle)
response to heatPlasminogen Bos taurus (cattle)
fibrinolysisPlasminogen Bos taurus (cattle)
tissue remodelingPlasminogen Bos taurus (cattle)
digestionTrypsin-1Homo sapiens (human)
extracellular matrix disassemblyTrypsin-1Homo sapiens (human)
proteolysisTrypsin-1Homo sapiens (human)
proteolysisTrypsin-2Homo sapiens (human)
digestionTrypsin-2Homo sapiens (human)
antimicrobial humoral responseTrypsin-2Homo sapiens (human)
extracellular matrix disassemblyTrypsin-2Homo sapiens (human)
positive regulation of cell growthTrypsin-2Homo sapiens (human)
collagen catabolic processTrypsin-2Homo sapiens (human)
positive regulation of cell adhesionTrypsin-2Homo sapiens (human)
adaptive immune responseProcathepsin LHomo sapiens (human)
proteolysisProcathepsin LHomo sapiens (human)
protein autoprocessingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host plasma membraneProcathepsin LHomo sapiens (human)
receptor-mediated endocytosis of virus by host cellProcathepsin LHomo sapiens (human)
antigen processing and presentationProcathepsin LHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IIProcathepsin LHomo sapiens (human)
collagen catabolic processProcathepsin LHomo sapiens (human)
zymogen activationProcathepsin LHomo sapiens (human)
enkephalin processingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host endosome membraneProcathepsin LHomo sapiens (human)
CD4-positive, alpha-beta T cell lineage commitmentProcathepsin LHomo sapiens (human)
symbiont entry into host cellProcathepsin LHomo sapiens (human)
antigen processing and presentation of peptide antigenProcathepsin LHomo sapiens (human)
proteolysis involved in protein catabolic processProcathepsin LHomo sapiens (human)
elastin catabolic processProcathepsin LHomo sapiens (human)
macrophage apoptotic processProcathepsin LHomo sapiens (human)
cellular response to thyroid hormone stimulusProcathepsin LHomo sapiens (human)
positive regulation of apoptotic signaling pathwayProcathepsin LHomo sapiens (human)
positive regulation of peptidase activityProcathepsin LHomo sapiens (human)
immune responseProcathepsin LHomo sapiens (human)
proteolysisCathepsin BHomo sapiens (human)
thyroid hormone generationCathepsin BHomo sapiens (human)
collagen catabolic processCathepsin BHomo sapiens (human)
epithelial cell differentiationCathepsin BHomo sapiens (human)
regulation of apoptotic processCathepsin BHomo sapiens (human)
decidualizationCathepsin BHomo sapiens (human)
symbiont entry into host cellCathepsin BHomo sapiens (human)
proteolysis involved in protein catabolic processCathepsin BHomo sapiens (human)
cellular response to thyroid hormone stimulusCathepsin BHomo sapiens (human)
metanephros developmentPro-cathepsin HHomo sapiens (human)
T cell mediated cytotoxicityPro-cathepsin HHomo sapiens (human)
adaptive immune responsePro-cathepsin HHomo sapiens (human)
immune response-regulating signaling pathwayPro-cathepsin HHomo sapiens (human)
proteolysisPro-cathepsin HHomo sapiens (human)
apoptotic processPro-cathepsin HHomo sapiens (human)
positive regulation of cell population proliferationPro-cathepsin HHomo sapiens (human)
positive regulation of gene expressionPro-cathepsin HHomo sapiens (human)
positive regulation of epithelial cell migrationPro-cathepsin HHomo sapiens (human)
neuropeptide catabolic processPro-cathepsin HHomo sapiens (human)
bradykinin catabolic processPro-cathepsin HHomo sapiens (human)
positive regulation of peptidase activityPro-cathepsin HHomo sapiens (human)
antigen processing and presentationPro-cathepsin HHomo sapiens (human)
positive regulation of cell migrationPro-cathepsin HHomo sapiens (human)
zymogen activationPro-cathepsin HHomo sapiens (human)
protein destabilizationPro-cathepsin HHomo sapiens (human)
response to retinoic acidPro-cathepsin HHomo sapiens (human)
membrane protein proteolysisPro-cathepsin HHomo sapiens (human)
negative regulation of apoptotic processPro-cathepsin HHomo sapiens (human)
surfactant homeostasisPro-cathepsin HHomo sapiens (human)
positive regulation of angiogenesisPro-cathepsin HHomo sapiens (human)
dichotomous subdivision of terminal units involved in lung branchingPro-cathepsin HHomo sapiens (human)
ERK1 and ERK2 cascadePro-cathepsin HHomo sapiens (human)
cellular response to thyroid hormone stimulusPro-cathepsin HHomo sapiens (human)
positive regulation of apoptotic signaling pathwayPro-cathepsin HHomo sapiens (human)
proteolysis involved in protein catabolic processPro-cathepsin HHomo sapiens (human)
immune responsePro-cathepsin HHomo sapiens (human)
proteolysisTrypsin-3Homo sapiens (human)
digestionTrypsin-3Homo sapiens (human)
antimicrobial humoral responseTrypsin-3Homo sapiens (human)
zymogen activationTrypsin-3Homo sapiens (human)
endothelial cell migrationTrypsin-3Homo sapiens (human)
collagen catabolic processCathepsin KHomo sapiens (human)
mitophagyCathepsin KHomo sapiens (human)
intramembranous ossificationCathepsin KHomo sapiens (human)
proteolysisCathepsin KHomo sapiens (human)
thyroid hormone generationCathepsin KHomo sapiens (human)
apoptotic processCathepsin KHomo sapiens (human)
response to organic cyclic compoundCathepsin KHomo sapiens (human)
extracellular matrix disassemblyCathepsin KHomo sapiens (human)
collagen catabolic processCathepsin KHomo sapiens (human)
response to insulinCathepsin KHomo sapiens (human)
cellular response to zinc ion starvationCathepsin KHomo sapiens (human)
bone resorptionCathepsin KHomo sapiens (human)
response to ethanolCathepsin KHomo sapiens (human)
proteolysis involved in protein catabolic processCathepsin KHomo sapiens (human)
negative regulation of cartilage developmentCathepsin KHomo sapiens (human)
cellular response to tumor necrosis factorCathepsin KHomo sapiens (human)
cellular response to transforming growth factor beta stimulusCathepsin KHomo sapiens (human)
mononuclear cell differentiationCathepsin KHomo sapiens (human)
positive regulation of apoptotic signaling pathwayCathepsin KHomo sapiens (human)
positive regulation of peptidase activityCathepsin KHomo sapiens (human)
immune responseCathepsin KHomo sapiens (human)
proteolysisHepatocyte growth factor activatorHomo sapiens (human)
blood coagulationHepatocyte growth factor activatorHomo sapiens (human)
zymogen activationHepatocyte growth factor activatorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IITransmembrane protease serine 6Homo sapiens (human)
intracellular iron ion homeostasisTransmembrane protease serine 6Homo sapiens (human)
extracellular matrix disassemblyTransmembrane protease serine 6Homo sapiens (human)
BMP signaling pathwayTransmembrane protease serine 6Homo sapiens (human)
negative regulation of BMP signaling pathwayTransmembrane protease serine 6Homo sapiens (human)
collagen catabolic processTransmembrane protease serine 6Homo sapiens (human)
membrane protein proteolysisTransmembrane protease serine 6Homo sapiens (human)
negative regulation of DNA-templated transcriptionTransmembrane protease serine 6Homo sapiens (human)
positive regulation of transcription by RNA polymerase IITransmembrane protease serine 6Homo sapiens (human)
multicellular organismal-level iron ion homeostasisTransmembrane protease serine 6Homo sapiens (human)
self proteolysisTransmembrane protease serine 6Homo sapiens (human)
neural tube closureSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
proteolysisSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
protein catabolic processSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
keratinocyte differentiationSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
epithelial cell morphogenesis involved in placental branchingSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (29)

Processvia Protein(s)Taxonomy
serine-type endopeptidase activityProthrombin Bos taurus (cattle)
calcium ion bindingProthrombin Bos taurus (cattle)
protein bindingProthrombin Bos taurus (cattle)
fibrinogen bindingProthrombin Bos taurus (cattle)
protease bindingPlasminogenHomo sapiens (human)
endopeptidase activityPlasminogenHomo sapiens (human)
serine-type endopeptidase activityPlasminogenHomo sapiens (human)
signaling receptor bindingPlasminogenHomo sapiens (human)
protein bindingPlasminogenHomo sapiens (human)
serine-type peptidase activityPlasminogenHomo sapiens (human)
enzyme bindingPlasminogenHomo sapiens (human)
kinase bindingPlasminogenHomo sapiens (human)
protein domain specific bindingPlasminogenHomo sapiens (human)
apolipoprotein bindingPlasminogenHomo sapiens (human)
protein-folding chaperone bindingPlasminogenHomo sapiens (human)
protein antigen bindingPlasminogenHomo sapiens (human)
endopeptidase activityCationic trypsinBos taurus (cattle)
serine-type endopeptidase activityCationic trypsinBos taurus (cattle)
protein bindingCationic trypsinBos taurus (cattle)
metal ion bindingCationic trypsinBos taurus (cattle)
serpin family protein bindingCationic trypsinBos taurus (cattle)
serine-type endopeptidase activityPlasma kallikreinHomo sapiens (human)
protein bindingPlasma kallikreinHomo sapiens (human)
serine-type endopeptidase activitySerine protease hepsinHomo sapiens (human)
protein bindingSerine protease hepsinHomo sapiens (human)
peptidase activitySerine protease hepsinHomo sapiens (human)
serine-type peptidase activitySerine protease hepsinHomo sapiens (human)
serine-type exopeptidase activitySerine protease hepsinHomo sapiens (human)
serine-type endopeptidase activityPlasminogen Bos taurus (cattle)
signaling receptor bindingPlasminogen Bos taurus (cattle)
protein bindingPlasminogen Bos taurus (cattle)
protein domain specific bindingPlasminogen Bos taurus (cattle)
serine-type endopeptidase activityTrypsin-1Homo sapiens (human)
metal ion bindingTrypsin-1Homo sapiens (human)
metalloendopeptidase activityTrypsin-2Homo sapiens (human)
serine-type endopeptidase activityTrypsin-2Homo sapiens (human)
calcium ion bindingTrypsin-2Homo sapiens (human)
protein bindingTrypsin-2Homo sapiens (human)
serine-type peptidase activityTrypsin-2Homo sapiens (human)
endopeptidase activityCathepsin BBos taurus (cattle)
fibronectin bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activityProcathepsin LHomo sapiens (human)
protein bindingProcathepsin LHomo sapiens (human)
collagen bindingProcathepsin LHomo sapiens (human)
cysteine-type peptidase activityProcathepsin LHomo sapiens (human)
histone bindingProcathepsin LHomo sapiens (human)
proteoglycan bindingProcathepsin LHomo sapiens (human)
serpin family protein bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activityCathepsin BHomo sapiens (human)
protein bindingCathepsin BHomo sapiens (human)
collagen bindingCathepsin BHomo sapiens (human)
peptidase activityCathepsin BHomo sapiens (human)
cysteine-type peptidase activityCathepsin BHomo sapiens (human)
proteoglycan bindingCathepsin BHomo sapiens (human)
endopeptidase activityPro-cathepsin HHomo sapiens (human)
aminopeptidase activityPro-cathepsin HHomo sapiens (human)
cysteine-type endopeptidase activityPro-cathepsin HHomo sapiens (human)
serine-type endopeptidase activityPro-cathepsin HHomo sapiens (human)
protein bindingPro-cathepsin HHomo sapiens (human)
peptidase activityPro-cathepsin HHomo sapiens (human)
cysteine-type peptidase activityPro-cathepsin HHomo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processPro-cathepsin HHomo sapiens (human)
HLA-A specific activating MHC class I receptor activityPro-cathepsin HHomo sapiens (human)
thyroid hormone bindingPro-cathepsin HHomo sapiens (human)
serine-type endopeptidase activityTrypsin-3Homo sapiens (human)
calcium ion bindingTrypsin-3Homo sapiens (human)
protein bindingTrypsin-3Homo sapiens (human)
serine-type peptidase activityTrypsin-3Homo sapiens (human)
fibronectin bindingCathepsin KHomo sapiens (human)
cysteine-type endopeptidase activityCathepsin KHomo sapiens (human)
serine-type endopeptidase activityCathepsin KHomo sapiens (human)
protein bindingCathepsin KHomo sapiens (human)
collagen bindingCathepsin KHomo sapiens (human)
cysteine-type peptidase activityCathepsin KHomo sapiens (human)
proteoglycan bindingCathepsin KHomo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processCathepsin KHomo sapiens (human)
protein bindingHepatocyte growth factor activatorHomo sapiens (human)
serine-type peptidase activityHepatocyte growth factor activatorHomo sapiens (human)
serine-type endopeptidase activityHepatocyte growth factor activatorHomo sapiens (human)
metalloendopeptidase activityTransmembrane protease serine 6Homo sapiens (human)
serine-type endopeptidase activityTransmembrane protease serine 6Homo sapiens (human)
protein bindingTransmembrane protease serine 6Homo sapiens (human)
serine-type endopeptidase activitySuppressor of tumorigenicity 14 proteinHomo sapiens (human)
serine-type peptidase activitySuppressor of tumorigenicity 14 proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (42)

Processvia Protein(s)Taxonomy
extracellular regionPlasminogenHomo sapiens (human)
extracellular spacePlasminogenHomo sapiens (human)
plasma membranePlasminogenHomo sapiens (human)
external side of plasma membranePlasminogenHomo sapiens (human)
cell surfacePlasminogenHomo sapiens (human)
platelet alpha granule lumenPlasminogenHomo sapiens (human)
collagen-containing extracellular matrixPlasminogenHomo sapiens (human)
extracellular exosomePlasminogenHomo sapiens (human)
blood microparticlePlasminogenHomo sapiens (human)
Schaffer collateral - CA1 synapsePlasminogenHomo sapiens (human)
glutamatergic synapsePlasminogenHomo sapiens (human)
extracellular spacePlasminogenHomo sapiens (human)
serine protease inhibitor complexCationic trypsinBos taurus (cattle)
extracellular regionPlasma kallikreinHomo sapiens (human)
extracellular spacePlasma kallikreinHomo sapiens (human)
plasma membranePlasma kallikreinHomo sapiens (human)
extracellular exosomePlasma kallikreinHomo sapiens (human)
nuclear membraneSerine protease hepsinHomo sapiens (human)
endoplasmic reticulum membraneSerine protease hepsinHomo sapiens (human)
plasma membraneSerine protease hepsinHomo sapiens (human)
cell-cell junctionSerine protease hepsinHomo sapiens (human)
cell surfaceSerine protease hepsinHomo sapiens (human)
membraneSerine protease hepsinHomo sapiens (human)
apical plasma membraneSerine protease hepsinHomo sapiens (human)
neuronal cell bodySerine protease hepsinHomo sapiens (human)
extracellular exosomeSerine protease hepsinHomo sapiens (human)
extracellular regionTrypsin-1Homo sapiens (human)
collagen-containing extracellular matrixTrypsin-1Homo sapiens (human)
blood microparticleTrypsin-1Homo sapiens (human)
extracellular spaceTrypsin-1Homo sapiens (human)
extracellular regionTrypsin-2Homo sapiens (human)
extracellular spaceTrypsin-2Homo sapiens (human)
extracellular matrixTrypsin-2Homo sapiens (human)
azurophil granule lumenTrypsin-2Homo sapiens (human)
extracellular spaceTrypsin-2Homo sapiens (human)
lysosomeCathepsin BBos taurus (cattle)
apical plasma membraneCathepsin BBos taurus (cattle)
melanosomeCathepsin BBos taurus (cattle)
extracellular regionProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
nucleusProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
multivesicular bodyProcathepsin LHomo sapiens (human)
Golgi apparatusProcathepsin LHomo sapiens (human)
plasma membraneProcathepsin LHomo sapiens (human)
apical plasma membraneProcathepsin LHomo sapiens (human)
endolysosome lumenProcathepsin LHomo sapiens (human)
chromaffin granuleProcathepsin LHomo sapiens (human)
lysosomal lumenProcathepsin LHomo sapiens (human)
intracellular membrane-bounded organelleProcathepsin LHomo sapiens (human)
collagen-containing extracellular matrixProcathepsin LHomo sapiens (human)
extracellular exosomeProcathepsin LHomo sapiens (human)
endocytic vesicle lumenProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
collagen-containing extracellular matrixCathepsin BHomo sapiens (human)
extracellular regionCathepsin BHomo sapiens (human)
extracellular spaceCathepsin BHomo sapiens (human)
lysosomeCathepsin BHomo sapiens (human)
external side of plasma membraneCathepsin BHomo sapiens (human)
apical plasma membraneCathepsin BHomo sapiens (human)
endolysosome lumenCathepsin BHomo sapiens (human)
melanosomeCathepsin BHomo sapiens (human)
perinuclear region of cytoplasmCathepsin BHomo sapiens (human)
collagen-containing extracellular matrixCathepsin BHomo sapiens (human)
extracellular exosomeCathepsin BHomo sapiens (human)
peptidase inhibitor complexCathepsin BHomo sapiens (human)
ficolin-1-rich granule lumenCathepsin BHomo sapiens (human)
extracellular spaceCathepsin BHomo sapiens (human)
lysosomeCathepsin BHomo sapiens (human)
extracellular regionPro-cathepsin HHomo sapiens (human)
extracellular spacePro-cathepsin HHomo sapiens (human)
lysosomePro-cathepsin HHomo sapiens (human)
cytosolPro-cathepsin HHomo sapiens (human)
secretory granule lumenPro-cathepsin HHomo sapiens (human)
cytoplasmic ribonucleoprotein granulePro-cathepsin HHomo sapiens (human)
intracellular membrane-bounded organellePro-cathepsin HHomo sapiens (human)
collagen-containing extracellular matrixPro-cathepsin HHomo sapiens (human)
extracellular exosomePro-cathepsin HHomo sapiens (human)
alveolar lamellar bodyPro-cathepsin HHomo sapiens (human)
multivesicular body lumenPro-cathepsin HHomo sapiens (human)
tertiary granule lumenPro-cathepsin HHomo sapiens (human)
ficolin-1-rich granule lumenPro-cathepsin HHomo sapiens (human)
extracellular spacePro-cathepsin HHomo sapiens (human)
lysosomePro-cathepsin HHomo sapiens (human)
extracellular regionTrypsin-3Homo sapiens (human)
extracellular spaceTrypsin-3Homo sapiens (human)
tertiary granule lumenTrypsin-3Homo sapiens (human)
extracellular spaceTrypsin-3Homo sapiens (human)
extracellular regionCathepsin KHomo sapiens (human)
extracellular spaceCathepsin KHomo sapiens (human)
nucleoplasmCathepsin KHomo sapiens (human)
lysosomeCathepsin KHomo sapiens (human)
external side of plasma membraneCathepsin KHomo sapiens (human)
apical plasma membraneCathepsin KHomo sapiens (human)
endolysosome lumenCathepsin KHomo sapiens (human)
lysosomal lumenCathepsin KHomo sapiens (human)
intracellular membrane-bounded organelleCathepsin KHomo sapiens (human)
extracellular spaceCathepsin KHomo sapiens (human)
lysosomeCathepsin KHomo sapiens (human)
extracellular regionHepatocyte growth factor activatorHomo sapiens (human)
cytosolHepatocyte growth factor activatorHomo sapiens (human)
rough endoplasmic reticulumHepatocyte growth factor activatorHomo sapiens (human)
extracellular spaceHepatocyte growth factor activatorHomo sapiens (human)
extracellular spaceTransmembrane protease serine 6Homo sapiens (human)
plasma membraneTransmembrane protease serine 6Homo sapiens (human)
plasma membraneTransmembrane protease serine 6Homo sapiens (human)
extracellular spaceSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
plasma membraneSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
external side of plasma membraneSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
basolateral plasma membraneSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (98)

Assay IDTitleYearJournalArticle
AID50473Inhibitory activity against Cathepsin B at a concentration of 200 ng/mL1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Tokaramide A, a new cathepsin B inhibitor from the marine sponge Theonella aff. mirabilis.
AID50272Inhibition of human cathepsin B1998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
Synthesis of peptide aldehyde derivatives as selective inhibitors of human cathepsin L and their inhibitory effect on bone resorption.
AID1125415Inhibition of human liver cathepsin H2014European journal of medicinal chemistry, Apr-22, Volume: 77Acyl hydrazides and triazoles as novel inhibitors of mammalian cathepsin B and cathepsin H.
AID1698173Binding affinity to chymotrypsin (unknown origin) assessed as change in melting temperature at 200 uM incubated for 15 mins by scanning fluorimetry2020Journal of natural products, 10-23, Volume: 83, Issue:10
Decoding the Papain Inhibitor from
AID1125417Inhibition of cathepsin H in goat liver using Leu-betaNA as substrate at 10 uM after 30 mins by colorimetric analysis2014European journal of medicinal chemistry, Apr-22, Volume: 77Acyl hydrazides and triazoles as novel inhibitors of mammalian cathepsin B and cathepsin H.
AID581975Inhibition of Cysteine protease falcipain-3 in Plasmodium falciparum HB3-leuR1 mutant infected erythrocytes assessed as slowing of substrate hydrolysis by Z-Phe-Arg-AMC substrate hydrolysis assay2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.
AID750031Inhibition of human liver cathepsin B2013Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11
Development of cell-active non-peptidyl inhibitors of cysteine cathepsins.
AID1179618Inhibition of human liver cathepsin B2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
SAR studies of differently functionalized chalcones based hydrazones and their cyclized derivatives as inhibitors of mammalian cathepsin B and cathepsin H.
AID581968Reduction in formation of hemozoin crystals in wild type Plasmodium falciparum HB3 infected in erythrocytes at 100 uM for 6 hrs by transmission electron microscopy2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.
AID581965Inhibition of Cysteine protease falcipain-3 in Plasmodium falciparum HB3 infected erythrocytes by Z-Phe-Arg-AMC substrate hydrolysis assay2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.
AID580316Antimalarial activity against chloroquine-susceptible Plasmodium berghei ANKA assessed as inhibition of trophozoite extract-mediated mouse hemoglobin hydrolysis at 10 mM after 18 hrs by SDS-PAGE2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Synthesis and biological evaluation of benzimidazole-5-carbohydrazide derivatives as antimalarial, cytotoxic and antitubercular agents.
AID581969Reduction in formation of hemozoin crystals in leupeptin resistant-Plasmodium falciparum HB3-leuR1 mutant infected in erythrocytes at 100 uM for 6 hrs by transmission electron microscopy2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.
AID1125409Inhibition of cathepsin H in goat liver assessed as residual enzyme activity using Leu-betaNA as substrate at 0.01 x 10'-4 M after 30 mins by colorimetric analysis relative to control2014European journal of medicinal chemistry, Apr-22, Volume: 77Acyl hydrazides and triazoles as novel inhibitors of mammalian cathepsin B and cathepsin H.
AID51350Inhibition of human cathepsin L.1998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
Synthesis of peptide aldehyde derivatives as selective inhibitors of human cathepsin L and their inhibitory effect on bone resorption.
AID381606Inhibition of human C3bBb convertase assessed as C3 cleavage at 1 mM after 30 mins by 12% gel analysis2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Profiling the enzymatic properties and inhibition of human complement factor B.
AID581970Reduction in hemozoin production in wild type Plasmodium falciparum HB3 infected in erythrocytes at 50 uM for 18 hrs by transmission electron microscopy2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.
AID603219Inhibition of Plasmodium falciparum recombinant refolded falcipain 2 activity using ZFR-AMC as a substrate after 30 mins by fluorimetric assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Design and synthesis of protein-protein interaction mimics as Plasmodium falciparum cysteine protease, falcipain-2 inhibitors.
AID1698170Inhibition of chymotrypsin (unknown origin) using sucAAPFamc substrate preincubated for 10 mins followed by addition of substrate and measured every 30 sec for 60 mins by fluorescence based assay2020Journal of natural products, 10-23, Volume: 83, Issue:10
Decoding the Papain Inhibitor from
AID1432750Competitive inhibition of recombinant human cathepsin K expressed in Pichia pastoris using Z-FR-MCA as substrate by Dixon plot method2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Leupeptazin, a highly modified tripeptide isolated from cultures of a Streptomyces sp. inhibits cathepsin K.
AID1179620Competitive inhibition of goat brain cathepsin B2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
SAR studies of differently functionalized chalcones based hydrazones and their cyclized derivatives as inhibitors of mammalian cathepsin B and cathepsin H.
AID1179622Inhibition of goat liver cathepsin H assessed as enzyme activity at 10 uM using BANA substrate pre-incubated 30 mins before substrate addition by colorimetry (Rvb = 3.70 +/- 0.0387 nmol/min/ml)2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
SAR studies of differently functionalized chalcones based hydrazones and their cyclized derivatives as inhibitors of mammalian cathepsin B and cathepsin H.
AID499180Inhibition of human recombinant matriptase 2 expressed in HEK293 cells in conditioned medium after 20 mins2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Identification of the first low-molecular-weight inhibitors of matriptase-2.
AID1125416Inhibition of cathepsin B in goat liver using alpha-N-benzoyl-D,L-arginine-2-naphthylamide as substrate at 1 uM pretreated with enzyme for 30 mins prior to substrate challenge by colorimetric analysis2014European journal of medicinal chemistry, Apr-22, Volume: 77Acyl hydrazides and triazoles as novel inhibitors of mammalian cathepsin B and cathepsin H.
AID581973Inhibition of Cysteine protease falcipain-2 in Plasmodium falciparum HB3-leuR1 mutant infected erythrocytes assessed as slowing of substrate hydrolysis by Z-Phe-Arg-AMC substrate hydrolysis assay2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.
AID396979Antimalarial activity as inhibition of chloroquine-resistant Plasmodium falciparum mediated mice (Mus musculus) hemoglobin hydrolysis at 5 mM after 18 hrs2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Synthesis of chlorovinyl sulfones as structural analogs of chalcones and their antiplasmodial activities.
AID381605Inhibition of human C3bBb convertase assessed as C3 cleavage at 1 mM after 30 mins by 7% gel analysis2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Profiling the enzymatic properties and inhibition of human complement factor B.
AID257053Inhibition of calpain I in C2C12 myoblasts loaded with Suc-Leu-Tyr-AMC at 10 uM2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Novel cell-penetrating alpha-keto-amide calpain inhibitors as potential treatment for muscular dystrophy.
AID1698172Binding affinity to papaya papain assessed as change in melting temperature at 200 uM incubated for 15 mins by scanning fluorimetry2020Journal of natural products, 10-23, Volume: 83, Issue:10
Decoding the Papain Inhibitor from
AID581972Inhibition of Cysteine protease falcipain-2 in Plasmodium falciparum HB3 infected erythrocytes assessed as slowing of substrate hydrolysis by Z-Phe-Arg-AMC substrate hydrolysis assay2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.
AID248410Inhibitory concentration against Plasmodium falciparum in FACS2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Synthesis and evaluation of new antimalarial phenylurenyl chalcone derivatives.
AID1125407Inhibition of cathepsin B in goat liver assessed as residual enzyme activity using alpha-N-benzoyl-D,L-arginine-2-naphthylamide as substrate at 0.001 x 10'-4 M pretreated with enzyme for 30 mins prior to substrate challenge by colorimetric analysis relati2014European journal of medicinal chemistry, Apr-22, Volume: 77Acyl hydrazides and triazoles as novel inhibitors of mammalian cathepsin B and cathepsin H.
AID1179619Inhibition of human liver cathepsin H2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
SAR studies of differently functionalized chalcones based hydrazones and their cyclized derivatives as inhibitors of mammalian cathepsin B and cathepsin H.
AID581962Antimicrobial activity against leupeptin resistant-Plasmodium falciparum HB3-leuR1 mutant infected in erythrocytes assessed as growth inhibition after 72 hrs by SYBR Green I-based fluorescence assay2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.
AID240752Inhibitory concentration against recombinant Falcipain-22005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Synthesis and evaluation of new antimalarial phenylurenyl chalcone derivatives.
AID229263Ratio of IC50 for Cathepsin B to that for Cathepsin L1998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
Synthesis of peptide aldehyde derivatives as selective inhibitors of human cathepsin L and their inhibitory effect on bone resorption.
AID215017Inhibition of trypsin with benzoyl-L-arginine ethyl ester as substrate1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Inhibition studies of some serine and thiol proteinases by new leupeptin analogues.
AID581960Inhibition of Cysteine protease falcipain-2 in Plasmodium falciparum HB3 infected erythrocytes by Z-Phe-Arg-AMC substrate hydrolysis assay2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.
AID1886555Inhibition of trypsin (unknown origin) using Nalpha-benzoyl-D/L-arginine-4-nitroanilide hydrochloride as substrate preincubated for 5 mins followed by substrate addition and measured upto 30 mins by absorbance based assay2022Journal of natural products, 08-26, Volume: 85, Issue:8
Nostosin G and Spiroidesin B from the Cyanobacterium
AID50109Inhibition of cathepsin B with Cbz-L-lysine-p-nitrophenyl ester as substrate1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Inhibition studies of some serine and thiol proteinases by new leupeptin analogues.
AID294655Inhibition of hemoglobin hydrolysis in mouse erythrocytes at 5 mM after 18 hrs relative to control2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Synthesis and evaluation of sulfonylurea derivatives as novel antimalarials.
AID499182Inhibition of human recombinant matriptase catalytic domain expressed in HEK293 cells after 20 mins2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Identification of the first low-molecular-weight inhibitors of matriptase-2.
AID351454Inhibition of cathepsin B by spectrofluorimetry2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Natural polyprenylated benzophenones inhibiting cysteine and serine proteases.
AID1177403Inhibition of pig pancreas trypsin type IX-S2014Journal of natural products, Aug-22, Volume: 77, Issue:8
Nostosins, Trypsin Inhibitors Isolated from the Terrestrial Cyanobacterium Nostoc sp. Strain FSN.
AID50472Inhibitory activity against Cathepsin B at a concentration of 1 ng/mL1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Tokaramide A, a new cathepsin B inhibitor from the marine sponge Theonella aff. mirabilis.
AID95170Inhibition of kallikrein with benzoyl-L-arginine ethyl ester as substrate1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Inhibition studies of some serine and thiol proteinases by new leupeptin analogues.
AID50476Inhibitory activity against Cathepsin B at a concentration of 4 ng/mL1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Tokaramide A, a new cathepsin B inhibitor from the marine sponge Theonella aff. mirabilis.
AID499181Inhibition of human purified matriptase 2 catalytic domain expressed in HEK293 cells after 20 mins2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Identification of the first low-molecular-weight inhibitors of matriptase-2.
AID582101Antimicrobial activity against leupeptin resistant-Plasmodium falciparum HB3-leuR1 mutant infected in erythrocytes assessed as growth inhibition after 72 hrs in presence of PSAC antagonist NPF1 by SYBR Green I-based fluorescence assay2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.
AID1171342Ratio of Ki for matriptase (unknown origin) to Ki for recombinant HGFA (unknown origin)2014ACS medicinal chemistry letters, Nov-13, Volume: 5, Issue:11
Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.
AID157792Inhibition of plasmin with Val-L-Leu-L-lysine-p-nitroanilide as substrate1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Inhibition studies of some serine and thiol proteinases by new leupeptin analogues.
AID582100Activity of PSAS assessed as channel-mediated drug uptake measured by inhibition of papain-mediated substrate hydrolysis by leupeptin resistant-Plasmodium falciparum HB3-leuR1 infected erythrocyte cytosol harvested from cells incubated at 40 uM for 15 min2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.
AID50478Inhibitory activity against Cathepsin B at a concentration of 70 ng/mL1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Tokaramide A, a new cathepsin B inhibitor from the marine sponge Theonella aff. mirabilis.
AID50480Inhibitory activity against Cathepsin B at a concentration of 900 ng/mL1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Tokaramide A, a new cathepsin B inhibitor from the marine sponge Theonella aff. mirabilis.
AID50469Inhibitory activity against Cathepsin B at a concentration of 1000 ng/mL1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Tokaramide A, a new cathepsin B inhibitor from the marine sponge Theonella aff. mirabilis.
AID581974Inhibition of Cysteine protease falcipain-3 in Plasmodium falciparum HB3 infected erythrocytes assessed as slowing of substrate hydrolysis by Z-Phe-Arg-AMC substrate hydrolysis assay2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.
AID581961Induction of parasite morphology changes in wild type Plasmodium falciparum HB3 infected in erythrocytes assessed as occurrence of enlarged digestive vacuoles by transmission electron microscopy2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.
AID374060Antimalarial activity against chloroquine-sensitive Plasmodium berghei ANKA infected BALB/c mice (Mus musculus) erythrocytes at 10 uM after 18 hrs as reduced hemoglobin hydrolysis2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Synthesis and antimalarial activity of pyrazolo and pyrimido benzothiazine dioxide derivatives.
AID581963Induction of parasite morphology changes in leupeptin resistant-Plasmodium falciparum HB3-leuR1 mutant infected in erythrocytes assessed as occurrence of enlarged digestive vacuoles by transmission electron microscopy2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.
AID277074Inhibition of human Cathepsin K2006Bioorganic & medicinal chemistry letters, Dec-15, Volume: 16, Issue:24
Natural inhibitors targeting osteoclast-mediated bone resorption.
AID1125406Inhibition of cathepsin B in goat liver assessed as residual enzyme activity using alpha-N-benzoyl-D,L-arginine-2-naphthylamide as substrate at 0.01 x 10'-4 M pretreated with enzyme for 30 mins prior to substrate challenge by colorimetric analysis relativ2014European journal of medicinal chemistry, Apr-22, Volume: 77Acyl hydrazides and triazoles as novel inhibitors of mammalian cathepsin B and cathepsin H.
AID1171343Ratio of Ki for matriptase (unknown origin) to Ki for recombinant hepsin (unknown origin)2014ACS medicinal chemistry letters, Nov-13, Volume: 5, Issue:11
Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.
AID581966Inhibition of Cysteine protease falcipain-3 in Plasmodium falciparum HB3-leuR1 mutant infected erythrocytes by Z-Phe-Arg-AMC substrate hydrolysis assay2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.
AID50479Inhibitory activity against Cathepsin B at a concentration of 7 ng/mL1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Tokaramide A, a new cathepsin B inhibitor from the marine sponge Theonella aff. mirabilis.
AID1125413Competitive inhibition of goat brain cathepsin B2014European journal of medicinal chemistry, Apr-22, Volume: 77Acyl hydrazides and triazoles as novel inhibitors of mammalian cathepsin B and cathepsin H.
AID581971Reduction in hemozoin production in leupeptin resistant-Plasmodium falciparum HB3-leuR1 mutant infected in erythrocytes at 50 uM for 18 hrs by transmission electron microscopy2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.
AID581959Inhibition of Cysteine protease falcipain-2 in Plasmodium falciparum HB3-leuR1 mutant infected erythrocytes by Z-Phe-Arg-AMC substrate hydrolysis assay2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.
AID50463Inhibitory activity against Cathepsin B was determined1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Tokaramide A, a new cathepsin B inhibitor from the marine sponge Theonella aff. mirabilis.
AID582099Activity of PSAS assessed as channel-mediated drug uptake measured by inhibition of papain-mediated substrate hydrolysis by Plasmodium falciparum HB3 infected erythrocyte cytosol harvested from cells incubated at 40 uM for 15 mins in presence og PSAC anta2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.
AID1125408Inhibition of cathepsin H in goat liver assessed as residual enzyme activity using Leu-betaNA as substrate at 0.1 x 10'-4 M after 30 mins by colorimetric analysis relative to control2014European journal of medicinal chemistry, Apr-22, Volume: 77Acyl hydrazides and triazoles as novel inhibitors of mammalian cathepsin B and cathepsin H.
AID261351Inhibition of Leishmania donovani cysteine protease2006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory.
AID257051Inhibitory activity against porcine calpain I using Suc-Leu-Tyr-AMC fluorogenic substrate2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Novel cell-penetrating alpha-keto-amide calpain inhibitors as potential treatment for muscular dystrophy.
AID1177402Inhibition of pig pancreas trypsin type IX-S using Boc-Gln-Ala-Arg-MCA substrate by 7-amino-4-methylcoumarin release based spectrofluorometry2014Journal of natural products, Aug-22, Volume: 77, Issue:8
Nostosins, Trypsin Inhibitors Isolated from the Terrestrial Cyanobacterium Nostoc sp. Strain FSN.
AID1171340Inhibition of matriptase (unknown origin) using Boc-QAR-AMC as substrate by fluorescence assay2014ACS medicinal chemistry letters, Nov-13, Volume: 5, Issue:11
Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.
AID1171341Inhibition of recombinant hepsin (unknown origin) using Boc-QAR-AMC as substrate by fluorescence assay2014ACS medicinal chemistry letters, Nov-13, Volume: 5, Issue:11
Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.
AID582093Inhibition of PSAC-mediated sorbitol uptake in erythrocytes infected with leupeptin resistant-Plasmodium falciparum HB3-leuR1 at 50 uM2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.
AID1125414Inhibition of human liver cathepsin B2014European journal of medicinal chemistry, Apr-22, Volume: 77Acyl hydrazides and triazoles as novel inhibitors of mammalian cathepsin B and cathepsin H.
AID323993Inhibition of HRV14 3C protease at 1 mM2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
New anti-viral drugs for the treatment of the common cold.
AID582098Activity of PSAS assessed as channel-mediated drug uptake measured by inhibition of papain-mediated substrate hydrolysis by Plasmodium falciparum HB3 infected erythrocyte cytosol harvested from cells incubated at 40 uM for 15 mins by Z-Phe-Arg-AMC substra2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.
AID213261Inhibition of thrombin with benzoyl-Phe-Val-arginine- p-nitroanilide as substrate1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Inhibition studies of some serine and thiol proteinases by new leupeptin analogues.
AID378554Inhibition of plasmin2005Journal of natural products, Mar, Volume: 68, Issue:3
Sesquiterpenoids and plasmin-inhibitory flavonoids from Blumea balsamifera.
AID381968Antiparasitic activity against Plasmodium berghei ANKA infected BALB/c mice (Mus musculus) after 18 hrs as reduced hemoglobin proteolysis2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Synthesis, antimalarial activity, structure-activity relationship analysis of thieno-[3,2-b]benzothiazine S,S-dioxide analogs.
AID1698171Inhibition of papaya papain using cbzFRamc substrate preincubated for 10 mins followed by addition of substrate and measured every 30 sec for 60 mins by fluorescence based assay2020Journal of natural products, 10-23, Volume: 83, Issue:10
Decoding the Papain Inhibitor from
AID1558634Drug metabolism in H20 buffer assessed as conversion of hydrate form to aldehyde form by measuring half life at pH 5.8 by 1H NMR analysis2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Fibrinolysis Inhibitors: Potential Drugs for the Treatment and Prevention of Bleeding.
AID1125404Inhibition of cathepsin B in goat liver assessed as residual enzyme activity using alpha-N-benzoyl-D,L-arginine-2-naphthylamide as substrate at 0.1 x 10'-4 M pretreated with enzyme for 30 mins prior to substrate challenge by colorimetric analysis relative2014European journal of medicinal chemistry, Apr-22, Volume: 77Acyl hydrazides and triazoles as novel inhibitors of mammalian cathepsin B and cathepsin H.
AID1558633Drug metabolism in H20 buffer assessed as conversion of hemi-aminal form to aldehyde form by measuring half life at pH 5.8 by 1H NMR analysis2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Fibrinolysis Inhibitors: Potential Drugs for the Treatment and Prevention of Bleeding.
AID51214Compound was measured for inhibition of collagenolytic of human Cathepsin L1998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
Synthesis of peptide aldehyde derivatives as selective inhibitors of human cathepsin L and their inhibitory effect on bone resorption.
AID581964Antimicrobial activity against wild type Plasmodium falciparum HB3 infected in erythrocytes assessed as growth inhibition after 72 hrs by SYBR Green I-based fluorescence assay2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.
AID251721Inhibition of hemoglobin hydrolysis in mice (Mus musculus) infected with Plasmodium berghei at 10 uM2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Synthesis and evaluation of new antimalarial phenylurenyl chalcone derivatives.
AID50474Inhibitory activity against Cathepsin B at a concentration of 400 ng/mL1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Tokaramide A, a new cathepsin B inhibitor from the marine sponge Theonella aff. mirabilis.
AID581967Inhibition of PSAC-mediated sorbitol uptake in erythrocytes infected with Plasmodium falciparum HB3 at 50 uM2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.
AID50477Inhibitory activity against Cathepsin B at a concentration of 50 ng/mL1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Tokaramide A, a new cathepsin B inhibitor from the marine sponge Theonella aff. mirabilis.
AID50471Inhibitory activity against Cathepsin B at a concentration of 10 ng/mL1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Tokaramide A, a new cathepsin B inhibitor from the marine sponge Theonella aff. mirabilis.
AID1179623Inhibition of goat liver cathepsin B assessed as enzyme activity at 1 uM using BANA substrate pre-incubated 30 mins before substrate addition by colorimetry (Rvb = 5.65 +/- 0.0276 nmol/min/ml)2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
SAR studies of differently functionalized chalcones based hydrazones and their cyclized derivatives as inhibitors of mammalian cathepsin B and cathepsin H.
AID1171339Inhibition of recombinant HGFA (unknown origin) using Boc-QLR-AMC as substrate by chromogenic proteolytic assay2014ACS medicinal chemistry letters, Nov-13, Volume: 5, Issue:11
Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (922)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990325 (35.25)18.7374
1990's335 (36.33)18.2507
2000's178 (19.31)29.6817
2010's75 (8.13)24.3611
2020's9 (0.98)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 43.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index43.00 (24.57)
Research Supply Index6.85 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index69.94 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (43.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews9 (0.95%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other935 (99.05%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]